PARP inhibitors in BRCA mutation-associated ovarian cancer
Mené sur 173 patientes atteintes d'un cancer séreux ovarien de haut grade, récidivant et sensible aux sels de platines, cet essai international de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'olaparib, en combinaison avec du paclitaxel ou du carboplatine, suivi par un traitement d'entretien avec de l'olaparib seul
The development of poly(ADP-ribose) polymerase (PARP) inhibitors as a treatment for ovarian cancer was prompted by observations that BRCA gene mutations, which result in homologous recombination DNA repair deficiency, greatly increased the in-vitro sensitivity of cancer cells to these inhibitors—the concept of synthetic lethality. Clinically, this finding was reinforced by the subsequent proof-of-concept trial of the single-agent PARP inhibitor olaparib, the recognition that about 20% of unselecte ..
The Lancet Oncology , commentaire, 2013